Inceptionr LLC Sells 5,521 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Inceptionr LLC lessened its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 37.5% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 9,217 shares of the company’s stock after selling 5,521 shares during the quarter. Inceptionr LLC’s holdings in Apellis Pharmaceuticals were worth $294,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in APLS. Raymond James Financial Inc. purchased a new stake in shares of Apellis Pharmaceuticals in the fourth quarter worth $1,564,000. M&T Bank Corp purchased a new stake in Apellis Pharmaceuticals during the 4th quarter valued at about $216,000. Victory Capital Management Inc. increased its stake in Apellis Pharmaceuticals by 36.5% during the 4th quarter. Victory Capital Management Inc. now owns 562,269 shares of the company’s stock valued at $17,942,000 after purchasing an additional 150,363 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Apellis Pharmaceuticals by 4.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 996,748 shares of the company’s stock worth $31,806,000 after buying an additional 40,386 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC lifted its stake in shares of Apellis Pharmaceuticals by 2.0% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 115,045 shares of the company’s stock worth $3,671,000 after buying an additional 2,250 shares in the last quarter. Institutional investors own 96.29% of the company’s stock.

Apellis Pharmaceuticals Trading Down 1.1 %

Shares of APLS stock opened at $25.04 on Monday. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. The company has a market cap of $3.14 billion, a price-to-earnings ratio of -12.33 and a beta of 0.92. Apellis Pharmaceuticals, Inc. has a 1 year low of $23.77 and a 1 year high of $63.07. The firm has a fifty day moving average price of $29.08 and a 200-day moving average price of $31.01.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its earnings results on Friday, February 28th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.08. The company had revenue of $212.50 million for the quarter, compared to the consensus estimate of $197.92 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. Apellis Pharmaceuticals’s quarterly revenue was up 45.2% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.73) earnings per share. As a group, equities analysts predict that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Insider Activity at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, CFO Timothy Eugene Sullivan sold 2,170 shares of the firm’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $28.70, for a total transaction of $62,279.00. Following the sale, the chief financial officer now directly owns 88,100 shares of the company’s stock, valued at $2,528,470. This trade represents a 2.40 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO James George Chopas sold 1,096 shares of the stock in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of $30.43, for a total value of $33,351.28. Following the sale, the chief accounting officer now owns 48,138 shares of the company’s stock, valued at $1,464,839.34. This represents a 2.23 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 65,934 shares of company stock worth $1,950,261. 6.80% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on APLS shares. HC Wainwright reissued a “buy” rating and set a $57.00 price target on shares of Apellis Pharmaceuticals in a research report on Monday, March 3rd. Royal Bank of Canada reduced their target price on Apellis Pharmaceuticals from $26.00 to $25.00 and set a “sector perform” rating for the company in a report on Monday, March 3rd. Morgan Stanley began coverage on Apellis Pharmaceuticals in a report on Thursday, November 21st. They set an “equal weight” rating and a $31.00 price target on the stock. Wedbush reduced their price objective on Apellis Pharmaceuticals from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Monday, March 3rd. Finally, The Goldman Sachs Group decreased their target price on Apellis Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating for the company in a research report on Monday, March 3rd. Eight equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $45.53.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).